1
|
Kaufmann B, Raess E, Schmid FA, Bieri U, Scherer TP, Elleisy M, Donati OF, Rupp NJ, Moch H, Gorin MA, Mortezavi A, Eberli D. Focal therapy with high-intensity focused ultrasound for prostate cancer: 3-year outcomes from a prospective trial. BJU Int 2024; 133:413-424. [PMID: 37897088 DOI: 10.1111/bju.16213] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/29/2023]
Abstract
OBJECTIVE To assess the oncological and functional outcomes of focal high-intensity focused ultrasound (HIFU) in treating localised prostate cancer (PCa), a 3-year prospective study was undertaken using periodic post-ablation saturation biopsies. PATIENTS AND METHODS Men with two or fewer lesions of grade group (GG) ≤3 PCa were eligible for participation. Additional criteria included a prostate-specific antigen (PSA) level of ≤15 ng/mL, clinical T1c-T2, and a life expectancy of ≥10 years. The primary endpoint was failure-free survival (FFS), defined as absence of clinically significant PCa (csPCa) in- or out-of-field on protocol-mandated saturation biopsy, no whole-gland or systemic salvage treatment, PCa metastasis, or PCa-related death. Results are reported using two distinct definitions of csPCa: (i) the presence of any GG ≥2 and (ii) any GG ≥3 or core involvement of ≥6 mm. Secondary endpoints were functional patient-reported outcome measures addressing urinary, sexual, and bowel function. RESULTS A total of 91 patients were included: six (7%) with GG1 and 85 (93%) with GG ≥2. In all, 83 (91%) underwent at least one follow-up biopsy. Biopsy attendance at 6, 12, and 36 months was 84%, 67%, and 51%, respectively. The FFS at these time points for any GG ≥2 PCa was 79% (95% confidence interval [CI] 80-88%), 57% (95% CI 48-69%) and 44% (95% CI 34-56%), respectively. Using the second definition, FFS were 88% (95% CI 81-95%), 70% (95% CI 61-81%) and 65% (95% CI 55-77%), respectively. The 3-year cancer-specific survival was 100%, and freedom from metastasis was 99%. Magnetic resonance imaging (MRI) (negative predictive value of up to 89%, 95% CI 84-93%) and relative decrease of PSA values (P = 0.4) performed poorly in detecting residual disease. Urinary and bowel assessment returned to baseline questionnaire scores within 3 months. In all, 17 (21%) patients reported meaningful worsening in erectile function. A significant decrease of PCa related anxiety was observed. CONCLUSIONS Focal HIFU treatment for localised PCa shows excellent functional outcomes with half of the patients remaining cancer-free after 3 years. Whole-gland treatment was avoided in 81%. Early follow-up biopsies are crucial to change or continue the treatment modality at the right time, while the use of MRI and PSA in detecting PCa recurrence is uncertain.
Collapse
Affiliation(s)
- Basil Kaufmann
- Department of Urology, University Hospital of Zurich, Zurich, Switzerland
- Milton and Carroll Petrie Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Elisa Raess
- Department of Urology, University Hospital of Zurich, Zurich, Switzerland
| | - Florian A Schmid
- Department of Urology, University Hospital of Zurich, Zurich, Switzerland
| | - Uwe Bieri
- Department of Urology, University Hospital of Zurich, Zurich, Switzerland
| | - Thomas P Scherer
- Department of Urology, University Hospital of Zurich, Zurich, Switzerland
| | - Moustafa Elleisy
- Department of Urology, University Hospital of Zurich, Zurich, Switzerland
| | - Olivio F Donati
- Institute of Diagnostic and Interventional Radiology, University Hospital of Zurich, Zurich, Switzerland
- Radiology Hirslanden Zurich, Octorad AG, Zurich, Switzerland
| | - Niels J Rupp
- Department of Pathology and Molecular Pathology, University Hospital of Zurich, Zurich, Switzerland
| | - Holger Moch
- Department of Pathology and Molecular Pathology, University Hospital of Zurich, Zurich, Switzerland
| | - Michael A Gorin
- Milton and Carroll Petrie Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Ashkan Mortezavi
- Department of Urology, University Hospital of Basel, Basel, Switzerland
| | - Daniel Eberli
- Department of Urology, University Hospital of Zurich, Zurich, Switzerland
| |
Collapse
|
2
|
Kaufmann B, Fischer S, Athanasiou A, Lautenbach N, Wittig A, Bieri U, Schmid FA, von Stauffenberg F, Scherer T, Eberli D, Gorin MA, Schiess R, Poyet C. Evaluation of Proclarix in the diagnostic work-up of prostate cancer. BJUI Compass 2024; 5:297-303. [PMID: 38371198 PMCID: PMC10869654 DOI: 10.1002/bco2.293] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2023] [Accepted: 09/13/2023] [Indexed: 02/20/2024] Open
Abstract
Objectives The use of multiparametric magnetic resonance imaging (mpMRI) has been widely adopted in the diagnostic work-up for suspicious prostate cancer (PCa) and is recommended in most current guidelines. However, mpMRI lesions are often indeterminate and/or turn out to be false-positive on prostate biopsy. The aim of this work was to evaluate Proclarix, a biomarker test for the detection of relevant PCa, regarding its diagnostic value in all men before biopsy and in men with indeterminate lesions on mpMRI (PI-RADS 3) during work-up for PCa. Materials and Methods Men undergoing mpMRI-targeted and systematic biopsy of the prostate were prospectively enrolled. The Proclarix test was evaluated for the detection accuracy of clinically significant PCa (csPCa) defined as Grade Group ≥ 2 and its association to mpMRI results. Further, Proclarix's performance was also tested when adapted to prostate volume (Proclarix density) and performance compared to PSA density (PSAD). Results A total of 150 men with a median age of 65 years and median PSA of 5.8 ng/mL were included in this study. CsPCa was diagnosed in 65 (43%) men. Proclarix was significantly associated with csPCa and higher PI-RADS score (p < 0.001). At the pre-defined cut-off of 10%, Proclarix's sensitivity for csPCa was 94%, specificity 19%, negative predictive value 80% and positive predictive value 47%. Proclarix density showed the highest AUC for the detection of csPCa of 0.77 (95%CI: 0.69-0.85) compared to PSA, PSAD and Proclarix alone. Proclarix was able to identify all six csPCa in men with PI-RADS 3 lesions (n = 28), whereas PSAD missed two out of six. At optimized cut-offs, Proclarix density outperformed PSAD by potentially avoiding 41% of unnecessary biopsies. Conclusion Proclarix demonstrates high sensitivity in detecting csPCa but may still result in unnecessary biopsies. However, Proclarix density was able to outperform PSAD and Proclarix and was found to be useful in men with PI-RADS 3 findings by safely avoiding unnecessary biopsies without missing csPCa.
Collapse
Affiliation(s)
- Basil Kaufmann
- Department of UrologyUniversity Hospital ZurichZurichSwitzerland
- Milton and Carroll Petrie Department of UrologyIcahn School of Medicine at Mount SinaiNew YorkNew YorkUSA
| | - Sharon Fischer
- Department of UrologyUniversity Hospital ZurichZurichSwitzerland
| | | | | | | | - Uwe Bieri
- Department of UrologyUniversity Hospital ZurichZurichSwitzerland
| | | | | | - Thomas Scherer
- Department of UrologyUniversity Hospital ZurichZurichSwitzerland
| | - Daniel Eberli
- Department of UrologyUniversity Hospital ZurichZurichSwitzerland
| | - Michael A. Gorin
- Milton and Carroll Petrie Department of UrologyIcahn School of Medicine at Mount SinaiNew YorkNew YorkUSA
| | | | - Cédric Poyet
- Department of UrologyUniversity Hospital ZurichZurichSwitzerland
| |
Collapse
|
3
|
Heining FM, Bieri U, Niemann T, Maletzki P, Tschung C, Adank JP, Rössler F, Nocito A, Hefermehl LJ. The Transabdominal Lumbar Approach (TALA) for Robotic Renal Surgery-A Retrospective Single-Center Comparative Study and Step-by-Step Description of a Novel Approach. Cancers (Basel) 2024; 16:446. [PMID: 38275887 PMCID: PMC10814128 DOI: 10.3390/cancers16020446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2023] [Revised: 01/14/2024] [Accepted: 01/19/2024] [Indexed: 01/27/2024] Open
Abstract
The transperitoneal approach (TP) and the retroperitoneal approach (RP) are two common methods for performing nephrectomy or partial nephrectomy. However, both approaches face difficulties, such as trocar placement and limited working space (RP). TP is impaired in the case of dorsal tumors and dissection of the renal artery can be challenging due to the anatomic localization dorsally to the renal vein. A hybrid approach that combines both methods has been previously reported in a case series, but not evaluated systematically. This study proposes a modified hybrid approach, which we call the transabdominal lumbar approach (TALA), involving late robotic docking after elaborating the retroperitoneum using conventional laparoscopy. The study compares the last 20 consecutive patients who underwent RP and the last 20 patients who underwent TALA at our institution. The investigated variables include operative time and amount of blood loss, hospitalization duration, postoperative analgesia requirement, and postoperative complications. The study found no significant difference in operative time, blood loss, ischemia time, or hospital stay between the two groups. The TALA group had fewer complications regarding Clavien-Dindo category 3, but one complication of category 4. In Conclusion, TALA is a safe and promising approach that combines the advantages of RP and TP.
Collapse
Affiliation(s)
- Franziska Maria Heining
- Department of Surgery, Division of Urology, Kantonsspital Baden, 5404 Baden, Switzerland; (F.M.H.); (U.B.); (P.M.); (J.-P.A.)
| | - Uwe Bieri
- Department of Surgery, Division of Urology, Kantonsspital Baden, 5404 Baden, Switzerland; (F.M.H.); (U.B.); (P.M.); (J.-P.A.)
| | - Tilo Niemann
- Department of Radiology, Kantonsspital Baden, 5404 Baden, Switzerland;
| | - Philipp Maletzki
- Department of Surgery, Division of Urology, Kantonsspital Baden, 5404 Baden, Switzerland; (F.M.H.); (U.B.); (P.M.); (J.-P.A.)
| | - Christopher Tschung
- Department of Surgery, Division of Urology, Kantonsspital Baden, 5404 Baden, Switzerland; (F.M.H.); (U.B.); (P.M.); (J.-P.A.)
| | - Jean-Pascal Adank
- Department of Surgery, Division of Urology, Kantonsspital Baden, 5404 Baden, Switzerland; (F.M.H.); (U.B.); (P.M.); (J.-P.A.)
| | - Fabian Rössler
- Department of Surgery and Transplantation, University Hospital Zürich, University of Zürich, 8006 Zürich, Switzerland;
| | - Antonio Nocito
- Department of Surgery, Kantonsspital Baden, 5404 Baden, Switzerland;
| | - Lukas John Hefermehl
- Department of Surgery, Division of Urology, Kantonsspital Baden, 5404 Baden, Switzerland; (F.M.H.); (U.B.); (P.M.); (J.-P.A.)
| |
Collapse
|
4
|
Lautenschlager S, Strebel R, Ahmadi K, Birzele J, Gu A, Nowag A, Scherer T, Bieri U. Prostatic Abscesses in a Patient Receiving Tumor Necrosis Factor-Alpha Inhibitor Therapy for Hidradenitis Suppurativa: A Case Report. Cureus 2023; 15:e41820. [PMID: 37575812 PMCID: PMC10423008 DOI: 10.7759/cureus.41820] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/11/2023] [Indexed: 08/15/2023] Open
Abstract
This report is the first to present the case of a patient who developed bacterial abscess-forming prostatitis while undergoing treatment with adalimumab, a tumor necrosis factor-alpha blocking therapy, for hidradenitis suppurativa. A 36-year-old male presented with persistent anogenital pain and dysuria for approximately three weeks. Two days before presentation at the emergency room (ER), a rubber band ligation was performed to address suspected hemorrhoids stages I-II. In the ER, clinical and laboratory examinations suggested acute prostatitis, prompting the initiation of antibiotic therapy. In the absence of an adequate response, magnetic resonance imaging was performed, which identified a complex abscess and fistulation system originating from the right prostatic lobe. Following the insertion of a drain, adalimumab was discontinued, and antibiotic therapy was intensified, resulting in the resolution of the abscess. After six weeks, follow-up showed the patient to be free of symptoms. This case highlights a rare adverse event of patients using immunomodulating medications and may help physicians to manage similar cases in the future. Immunomodulating drugs can lead to the development of prostatic abscesses in young patients, necessitating attentive and careful clinical examination with a low threshold for further diagnostic workup in uncommon case presentations.
Collapse
Affiliation(s)
| | - Räto Strebel
- Department of Urology, Cantonal Hospital of Graubünden, Chur, CHE
| | - Khosrow Ahmadi
- Department of Urology, Cantonal Hospital of Graubünden, Chur, CHE
| | - Jan Birzele
- Department of Urology, Cantonal Hospital of Graubünden, Chur, CHE
| | - Alexander Gu
- Department of Urology, Cantonal Hospital of Graubünden, Chur, CHE
| | - Anna Nowag
- Department of Urology, Cantonal Hospital of Graubünden, Chur, CHE
| | - Thomas Scherer
- Department of Urology, University Hospital Zurich, Zurich, CHE
| | - Uwe Bieri
- Department of Urology, Cantonal Hospital of Graubünden, Chur, CHE
- Department of Urology, University Hospital Zurich, Zurich, CHE
| |
Collapse
|
5
|
Bieri U, Kranzbühler B, Wettstein MS, Fankhauser CD, Kaufmann BP, Seifert B, Bode PK, Poyet C, Lenggenhager D, Hermanns T. Limited Value of Bladder Wash Cytology During Follow-Up of Patients With Non-muscle Invasive Bladder Cancer. Cureus 2023; 15:e40283. [PMID: 37448431 PMCID: PMC10336741 DOI: 10.7759/cureus.40283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/11/2023] [Indexed: 07/15/2023] Open
Abstract
Aims We aimed to assess the performance of bladder wash cytology (BWC) in daily clinical practice in a pure follow-up cohort of patients previously diagnosed with non-muscle invasive bladder cancer (NMIBC). Materials and methods We analyzed 2064 BWCs derived from 314 patients followed for NMIBC (2003-2016). Follow-up investigations were performed using cystoscopy (CS) in combination with BWC. Patients with suspicious CS and/or positive BWC underwent bladder biopsy or transurethral resection. BWC was considered positive if malignant or suspicious cells were reported. Sensitivity (Sn) and specificity (Sp) were calculated for the entire cohort and separately for low-grade (LG) and high-grade (HG) tumors, and carcinoma in situ (CIS) subgroups. Results A total of 95 recurrences were detected, of which only three were detected by BWC alone. Overall, Sn and Sp of BWC were 17.9% and 99.5%, respectively. For LG disease, these numbers were 14.0% and 100%, and for HG disease, these were 22.2% and 99.1%, respectively. For patients with CIS at initial diagnosis, Sn and Sp were 11.0% and 71.4%, respectively. For isolated primary CIS, Sn was 50.0%, and Sp was 98.2%. Conclusion Routine use of BWC in the follow-up for NMIBC is of limited value even in HG tumors. In the presence of isolated primary CIS, adjunct BWC might be justified.
Collapse
Affiliation(s)
- Uwe Bieri
- Department of Urology, University Hospital Zürich, Zürich, CHE
| | | | | | | | | | - Burkhardt Seifert
- Epidemiology, Biostatistics and Prevention Institute, University of Zürich, Zürich, CHE
| | - Peter K Bode
- Department of Pathology and Molecular Pathology, University Hospital Zürich, Zürich, CHE
| | - Cédric Poyet
- Department of Urology, University Hospital Zürich, Zürich, CHE
| | - Daniela Lenggenhager
- Department of Pathology and Molecular Pathology, University Hospital Zürich, Zürich, CHE
| | - Thomas Hermanns
- Department of Urology, University Hospital Zürich, Zürich, CHE
| |
Collapse
|
6
|
Rössler F, Sachs A, Bieri U, Kuzmanic B, Ballova V, Schneider U, Singer G, Nocito A. Extranodal Diffuse Large B-cell Lymphoma With Primary Clinical Presentation as Acute Cholecystitis: A Case Report. Cureus 2023; 15:e37552. [PMID: 37193435 PMCID: PMC10183092 DOI: 10.7759/cureus.37552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/13/2023] [Indexed: 05/18/2023] Open
Abstract
This case describes a rare presentation of a diffuse large B-cell lymphoma not otherwise specified (DLBC NOS) in the gallbladder. We report the case of an 89-year-old male who initially presented with a two-week history of weakness and abdominal discomfort. We performed laparoscopic cholecystectomy for suspicion of acute cholecystitis. After the initial uneventful course, readmission occurred for persisting weakness a few weeks after surgery. Computed tomography revealed progressive retroperitoneal lymphadenopathy. With new emerging neurological symptoms, taking into account the histopathological findings of the gallbladder specimen, the diagnosis of DLBCL NOS was confirmed. Due to the rapid clinical deterioration and extranodal involvement, the patient opted against further therapy. When the suspicion of cholecystitis is inconclusive, rare differential diagnoses need to be considered. This analysis may improve the understanding of the presentation and course of DLBC NOS in abdominal organs and could form the basis for a systematic review to improve diagnosis and therapy.
Collapse
Affiliation(s)
- Fabian Rössler
- Department of Surgery and Transplantation, Universitätsspital Zürich, Zürich, CHE
| | - Alexandra Sachs
- Department of Internal Medicine, Spital Limmattal, Zürich, CHE
| | - Uwe Bieri
- Department of Urology, Kantonsspital Chur, Chur, CHE
| | - Boris Kuzmanic
- Department of Pathology, Kantonsspital Baden, Baden, CHE
| | | | - Ulrich Schneider
- Department of General, Visceral and Vascular Surgery, Kantonsspital Baden, Baden, CHE
| | - Gad Singer
- Department of Pathology, Kantonsspital Baden, Baden, CHE
| | - Antonio Nocito
- Department of General, Visceral and Vascular Surgery, Kantonsspital Baden, Baden, CHE
| |
Collapse
|
7
|
Bieri U, Enderlin D, Buser L, Wettstein MS, Eberli D, Moch H, Hermanns T, Poyet C. Modified immunoscore improves the prediction of progression-free survival in patients with non-muscle-invasive bladder cancer: A digital pathology study. Front Oncol 2022; 12:964672. [PMID: 36212478 PMCID: PMC9539272 DOI: 10.3389/fonc.2022.964672] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2022] [Accepted: 09/05/2022] [Indexed: 12/24/2022] Open
Abstract
Tumour-infiltrating lymphocytes (TIL), known to be of prognostic value in various solid tumours, have been in the focus of research in the last years. TIL are often quantified via IMMUNOSCORE ® (IS), a scoring system based on TIL cell densities. Recent studies were able to replicate these findings for muscle-invasive bladder cancer (MIBC), however data regarding non-muscle-invasive bladder cancer (NMIBC) are scarce. This study aimed to evaluate the value of a modified Immunoscore (mIS) as a predictive marker for NMIBC prognosis using tissue-micro-arrays (TMAs). We analysed two TMAs containing 316 samples from 158 patients with NMIBC, stained for CD3, CD8, CD45RO and FOXP3. Stained TIL were captured by digital pathology, cumulated, averaged, and reported as density (stained cells per mm²). The mIS was then constructed based on density of all four immune-cell types. Clinical, pathological and follow-up data were collected retrospectively. Univariable and multivariable cox regression analysis was performed to assess the potential value of mIS as a predictor for progression free survival (PFS) and recurrence-free-survival (RFS). Patients within "European Organisation for Research and Treatment of Cancer" (EORTC) risk groups were further substratified in high mIS and low mIS subgroups. Finally log-rank test was used to compare the different survival curves. The median age in our cohort was 68 years (Interquartile Range (IQR): 60 - 76), and 117 (74%) patients were male. A total of 26 patients (16.5%) were classified as EORTC low risk, 45 (28.5%) as intermediate risk and 87 (55.1%) as high risk. Patients in the EORTC high risk group with low mIS showed a shorter PFS in comparison to high mIS (HR 2.9, CI 0.79 - 11.0, p=0.082). In contrast, no predictive potential regarding PFS was observed in intermediate or low risk groups. Furthermore, mIS was not able to predict RFS in any EORTC risk group. mIS could be utilized to predict prognosis more accurately in high-risk patients with NMIBC by identifying those with higher or lower risk of progression. Therefore, mIS could be used to allocate these highrisk patients to more streamlined follow-up or more aggressive treatment strategies.
Collapse
Affiliation(s)
- Uwe Bieri
- Department of Urology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland
| | - Dominik Enderlin
- Department of Urology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland
| | - Lorenz Buser
- Department of Pathology and Molecular Pathology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland
| | - Marian S. Wettstein
- Department of Urology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland
| | - Daniel Eberli
- Department of Urology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland
| | - Holger Moch
- Department of Pathology and Molecular Pathology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland
| | - Thomas Hermanns
- Department of Urology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland
| | - Cédric Poyet
- Department of Urology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland
| |
Collapse
|
8
|
Bieri U, Scharl M, Sigg S, Szczerba BM, Morsy Y, Rüschoff JH, Schraml PH, Krauthammer M, Hefermehl LJ, Eberli D, Poyet C. Prospective observational study of the role of the microbiome in BCG responsiveness prediction (SILENT-EMPIRE): a study protocol. BMJ Open 2022; 12:e061421. [PMID: 35437256 PMCID: PMC9016396 DOI: 10.1136/bmjopen-2022-061421] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
INTRODUCTION The human microbiota, the community of micro-organisms in different cavities, has been increasingly linked with inflammatory and neoplastic diseases. While investigation into the gut microbiome has been robust, the urinary microbiome has only recently been described. Investigation into the relationship between bladder cancer (BC) and the bladder and the intestinal microbiome may elucidate a pathophysiological relationship between the two. The bladder or the intestinal microbiome or the interplay between both may also act as a non-invasive biomarker for tumour behaviour. While these associations have not yet been fully investigated, urologists have been manipulating the bladder microbiome for treatment of BC for more than 40 years, treating high grade non-muscle invasive BC (NMIBC) with intravesical BCG immunotherapy. Neither the association between the microbiome sampled directly from bladder tissue and the response to BCG-therapy nor the association between response to BCG-therapy with the faecal microbiome has been studied until now. A prognostic tool prior to initiation of BCG-therapy is still needed. METHODS AND ANALYSIS In patients with NMIBC bladder samples will be collected during surgery (bladder microbiome assessment), faecal samples (microbiome assessment), instrumented urine and blood samples (biobank) will also be taken. We will analyse the microbial community by 16S rDNA gene amplicon sequencing. The difference in alpha diversity (diversity of species within each sample) and beta diversity (change in species diversity) between BCG-candidates will be assessed. Subgroup analysis will be performed which will lead to the development of a clinical prediction model estimating risk of BCG-response. ETHICS AND DISSEMINATION The study has been approved by the Cantonal Ethics Committee Zurich (2021-01783) and it is being conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. Study results will be disseminated through peer-reviewed journals and national and international scientific conferences. TRIAL REGISTRATION NUMBER NCT05204199.
Collapse
Affiliation(s)
- Uwe Bieri
- Department of Urology, University Hospital Zurich, Zurich, Switzerland
| | - Michael Scharl
- Division of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland
| | - Silvan Sigg
- Department of Urology, University Hospital Zurich, Zurich, Switzerland
| | - Barbara Maria Szczerba
- Division of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland
| | - Yasser Morsy
- Division of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland
| | - Jan Hendrik Rüschoff
- Department of Pathology, and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Peter Hans Schraml
- Department of Pathology, and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Michael Krauthammer
- Comprehensive Cancer Center Zürich, University Hospital Zurich, Zurich, Switzerland
- Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland
| | | | - Daniel Eberli
- Department of Urology, University Hospital Zurich, Zurich, Switzerland
| | - Cédric Poyet
- Department of Urology, University Hospital Zurich, Zurich, Switzerland
| |
Collapse
|
9
|
Gu A, Oyo L, Grossmann NC, Wettstein MS, Kaufmann B, Bieri U, Poyet C, Hermanns T, Sulser T, Eberli D, Keller EX. Tumor stent for chronic ureteral obstruction: Which are predictors of stent failure? J Endourol 2021; 36:819-826. [PMID: 34969262 DOI: 10.1089/end.2021.0689] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
PURPOSE To identify predictors of UROSOFT® tumor stent failure. According to the manufacturer, this reinforced ureteral stent has a maximal dwell time of 6 months. Nonetheless, stent failure may reduce this maximal dwell time. METHODS All patients undergoing first-time UROSOFT® tumor stent insertion in our institution between 2010 and 2018 were considered for this retrospective analysis. Primary endpoint was stent failure and defined as premature stent exchange or percutaneous nephrostomy insertion. RESULTS 182 patients were available for analysis. Median age was 68 years. Causes for tumor stent placement were extrinsic ureteral obstruction in 144 patients (79 %) and intrinsic obstruction in 38 patients (21 %). Tumor stent failure free survival estimates at 1, 2, 3, 4 and 5 months were 89%, 83%, 76%, 65% and 52%, respectively. Patients with stent failure had significantly higher grade of hydronephrosis, higher urinary culture bacterial growth, higher serum WBC, higher CRP and lower eGFR at the time of re-intervention, compared to patients who underwent regular stent exchange. Of all baseline and perioperative parameters, we found bilateral insertion, intrinsic ureteral obstruction, and urinary tract infection (UTI) at time of tumor stent insertion to be significant and independent predictors of stent failure (all p < 0.05). CONCLUSION Despite a theoretical maximal dwell time of 6 months, around 50% of all cases are subject to premature stent failure. Predictors of stent failure are bilateral insertion, intrinsic ureteral obstruction, and UTI at the time of tumor stent insertion. Preoperative antibiotic therapy may impact on stent failure rate.
Collapse
Affiliation(s)
- Alexander Gu
- UniversitätsSpital Zürich, 27243, Urologie, Frauenklinikstrasse 10, Zurich, Switzerland, 8091;
| | - Lisa Oyo
- UniversitätsSpital Zürich, 27243, Urologie, Zurich, Switzerland;
| | | | | | - Basil Kaufmann
- UniversitätsSpital Zürich, 27243, Urologie, Zurich, Switzerland;
| | - Uwe Bieri
- UniversitätsSpital Zürich, 27243, Urologie, Zurich, Switzerland;
| | - Cédric Poyet
- UniversitätsSpital Zürich, 27243, Urologie, Zurich, Switzerland;
| | - Thomas Hermanns
- UniversitätsSpital Zürich, 27243, Urologie, Zurich, Zürich, Switzerland;
| | - Tullio Sulser
- UniversitätsSpital Zürich, 27243, Urologie, Zurich, Switzerland;
| | - Daniel Eberli
- UniversitätsSpital Zürich, 27243, Urologie, Zurich, Zürich, Switzerland;
| | | |
Collapse
|
10
|
Bieri U, Slieker J, Hefermehl LJ, Soppe S, Teufelberger G, Tedaldi R, Graf N, Bieri M, Nocito A. Randomised, quadruple blinded, placebo controlled, multicentre trial investigating prophylactic tamsulosin in prevention of postoperative urinary retention in men after endoscopic total extraperitoneal inguinal hernia repair (STOP-POUR trial): a study protocol. BMJ Open 2021; 11:e048911. [PMID: 34876420 PMCID: PMC8655554 DOI: 10.1136/bmjopen-2021-048911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
INTRODUCTION Postoperative urinary retention (POUR) is a common complication after inguinal hernia repair with a reported incidence up to 34%. It can be described as the inability to initiate urination or insufficient bladder emptying following surgery. It usually requires the use of catheterisation to empty the bladder in order to prevent further injury to the bladder or kidneys and to relief from pain. Tamsulosin is a medication that is commonly used in men with urinary symptoms related to an enlarged prostate. There is some evidence to suggest that it may also potentially be beneficial for preventing POUR. METHODS AND ANALYSIS This is a multicentre, blinded, prospective, phase IV randomised controlled trial with parallel allocation. Six hundred and thirty-four patients scheduled for elective endoscopic inguinal hernia repair surgery will be recruited. There will be effective (concealed) randomisation of the subjects to the intervention/control groups. Group assignment will be performed using a covariate-adaptive allocation procedure to provide a balance for selected covariates. The interventional group receives 0.4 mg tamsulosin hydrochloride and the control-group receives one placebo capsule matching the active study drug, both daily, starting from 5 days prior to the day of surgery, at the day of surgery and for 1 day following surgery. The primary outcome is any need for urinary catheterisation postoperatively as a binary outcome. Secondary outcome measures include postoperative pain, change in International Prostate Symptom Score from baseline prior to surgery to after surgery and hospital stay. ETHICS AND DISSEMINATION The study has been approved by the Northwestern and Central Switzerland Ethics Committee (2020-00569) and it is being conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. Study results will be disseminated through peer-reviewed journals and national and international scientific conferences. TRIAL REGISTRATION NUMBERS SNCTP000003904. NCT04491526.
Collapse
Affiliation(s)
- Uwe Bieri
- Department of Urology, University Hospital Zurich, Zurich, Switzerland
| | - Juliette Slieker
- Department for General, Visceral and Vascular Surgery, Kantonsspital Baden, Baden, Switzerland
| | - Lukas John Hefermehl
- Department of Surgery, Division of Urology, Kantonsspital Baden, Baden, Switzerland
| | - Sebastian Soppe
- Department for General, Visceral and Vascular Surgery, Kantonsspital Baden, Baden, Switzerland
| | | | - Regula Tedaldi
- Department of General Surgery, Spital Muri, Muri, Switzerland
| | | | - Marco Bieri
- Commissioning and Qualification Engineer, Rotkreuz, Switzerland
| | - Antonio Nocito
- Department for General, Visceral and Vascular Surgery, Kantonsspital Baden, Baden, Switzerland
| |
Collapse
|
11
|
Di Natale S, Slieker J, Soppe S, Bieri U, Keerl A, Nocito A. Risk Factors for Postoperative Urinary Retention After Endoscopic Hernia Repair: Age and Unilateral Operation make the Difference. World J Surg 2021; 45:3616-3622. [PMID: 34424402 DOI: 10.1007/s00268-021-06292-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/07/2021] [Indexed: 05/31/2023]
Abstract
BACKGROUND Postoperative urinary retention (POUR) is a common complication after inguinal hernia repair that may result in catheter-related infections or injuries, longer hospital stays, and thus, higher overall costs. Our aim was to assess the incidence of POUR after endoscopic total extraperitoneal (TEP) inguinal hernia repair and identify its risk factors. METHODS We retrospectively analyzed all data that were included in a prospective Hernia Database for patients undergoing a TEP inguinal hernia repair at our institution between July 2012 and May 2018. POUR was defined as the inability to urinate spontaneously after surgery, thus requiring a bladder catheter. RESULTS Data from 1570 patients were included. Sixty-five patients developed POUR, which was an incidence of 4.1%. In the univariate analysis, patients over 50 years of age (1.6% vs. 5.5%), patients with higher American Society of Anesthesiologists (ASA) score (ASA-1 2.7% vs. ASA-3 12.5%), previous prostate surgery (3.9% vs. 10.9%), unilateral operation (1.9% vs. 6.0%), and intraoperative drain placement (2.1% vs. 4.9%) developed POUR more often than younger patients. After multivariate adjustment, advanced age and unilateral surgery remained risk factors for POUR. CONCLUSION Advanced age and unilateral inguinal hernia repair, possibly due to a lack of catheterization, were risk factors for POUR. Due to increasing outpatient inguinal hernia repairs worldwide, it is imperative to identify patients who are at risk of POUR to apply prophylactic measures and reduce readmission, and thus, reduce health-care costs.
Collapse
Affiliation(s)
- S Di Natale
- Department of Surgery, Cantonal Hospital of Baden, Im Ergel 1, 5404, Baden, Switzerland
| | - J Slieker
- Department of Surgery, Cantonal Hospital of Baden, Im Ergel 1, 5404, Baden, Switzerland
| | - S Soppe
- Department of Surgery, Cantonal Hospital of Baden, Im Ergel 1, 5404, Baden, Switzerland
| | - U Bieri
- Department of Surgery, Cantonal Hospital of Baden, Im Ergel 1, 5404, Baden, Switzerland
| | - A Keerl
- Department of Surgery, Cantonal Hospital of Baden, Im Ergel 1, 5404, Baden, Switzerland
| | - A Nocito
- Department of Surgery, Cantonal Hospital of Baden, Im Ergel 1, 5404, Baden, Switzerland.
| |
Collapse
|
12
|
Bieri U, Buser L, Wettstein M, Sulser T, Saba K, Moch H, Hermanns T, Poyet C. Modified Immunoscore improves prediction of survival outcomes in patients undergoing radical cystectomy for bladder cancer. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33693-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
13
|
Rössler F, Keerl A, Bieri U, Slieker J, Nocito A. Natural Orifice Transluminal Endoscopic Surgery: Long-Term Experience with Hybrid Transvaginal Cholecystectomies. Surg Innov 2020; 27:594-601. [PMID: 32538319 DOI: 10.1177/1553350620932402] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Objective. To assess outcome and safety of 571 hybrid natural orifice transluminal endoscopic surgery (NOTES) cholecystectomies. Methods. We retrospectively analyzed all consecutive NOTES cholecystectomies performed at our center between June 2009 and January 2018. All procedures were performed using a hybrid transvaginal technique, including an umbilical small-size trocar. End points, calculated at discharge, 30 and up to 90 days postoperatively, included intra- and postoperative morbidity assessed by the validated Clavien-Dindo classification and the Comprehensive Complication Index (CCI). Special focus was held on outcome and necessity of pre- and postoperative gynecological examinations. Results. We performed 571 hybrid NOTES cholecystectomies within 9 years. The vast majority were elective, 9.6% were emergency cholecystectomies. 6.7% of patients developed at least one complication until discharge, most of them minor (≤grade II). 30- and 90-day complication rates were 10.7% and 11%, respectively. Mean CCI at discharge and postoperative days 30 and 90 was 1.45 (±6.4), 2.3 (±7.7), and 2.4 (±7.8), respectively. Major complications (≥grade IIIa) occurred in 1.6% of patients, and 4 patients required emergency reoperation. No mortality was observed. In 9.8%, an additional abdominal trocar was placed. All patients underwent routine gynecological examination, whereof only 5 were rejected for transvaginal access preoperatively. In no case transvaginal access was discontinued intraoperatively due to gynecological disease. Conclusion. Hybrid NOTES transvaginal cholecystectomy represents a safe and feasible alternative to standard laparoscopic cholecystectomy. Preoperative gynecological examination is no longer routinely necessary, as intraoperative assessment is adequate.
Collapse
Affiliation(s)
- Fabian Rössler
- Department for General, Visceral and Vascular Surgery, 30246Kantonsspital Baden, Switzerland
- Department of Surgery and Transplantation, 27243University Hospital Zurich, Switzerland
| | - Andreas Keerl
- Department for General, Visceral and Vascular Surgery, 30246Kantonsspital Baden, Switzerland
| | - Uwe Bieri
- Department for General, Visceral and Vascular Surgery, 30246Kantonsspital Baden, Switzerland
- Department of Urology, 27243University Hospital Zurich, Switzerland
| | - Juliette Slieker
- Department for General, Visceral and Vascular Surgery, 30246Kantonsspital Baden, Switzerland
| | - Antonio Nocito
- Department for General, Visceral and Vascular Surgery, 30246Kantonsspital Baden, Switzerland
| |
Collapse
|
14
|
Bieri U, Hübel K, Seeger H, Kulkarni GS, Sulser T, Hermanns T, Wettstein MS. Management of Active Surveillance-Eligible Prostate Cancer during Pretransplantation Workup of Patients with Kidney Failure: A Simulation Study. Clin J Am Soc Nephrol 2020; 15:822-829. [PMID: 32381585 PMCID: PMC7274295 DOI: 10.2215/cjn.14041119] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2019] [Accepted: 03/25/2020] [Indexed: 11/23/2022]
Abstract
BACKGROUND AND OBJECTIVES The general rule that every active malignancy is an absolute contraindication for kidney transplantation is challenged by kidney failure patients diagnosed with active surveillance-eligible prostate cancer during pretransplantation workup. Interdisciplinary treatment teams therefore often face the challenge of balancing the benefits of early kidney transplantation and the risk of metastatic progression. Hence, we compared the quality-adjusted life expectancy of different management strategies in kidney failure patients diagnosed with active surveillance-eligible prostate cancer during pretransplantation workup. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS A discrete event simulation model was developed on the basis of a systematic literature search, clinical guidelines, and expert opinion. After model validation and calibration, we simulated four management strategies in a hypothetical cohort of 100,000 patients: Definitive treatment (surgery or radiation therapy) and listing after a waiting period of 2 years, definitive treatment and immediate listing, active surveillance and listing after a waiting period of 2 years, and active surveillance and immediate listing. Individual patient results (quality-adjusted life years; QALYs) were aggregated into strategy-specific means (± SEs). RESULTS Active surveillance and immediate listing yielded the highest amount of quality-adjusted life expectancy (6.97 ± 0.01 QALYs) followed by definitive treatment and immediate listing (6.75 ± 0.01 QALYs). These two strategies involving immediate listing not only outperformed those incorporating a waiting period of 2 years (definitive treatment: 6.32 ± 0.01 QALYs; active surveillance: 6.59 ± 0.01 QALYs) but also yielded a higher proportion of successfully performed transplantations (72% and 74% versus 56% and 59%), with less time on hemodialysis on average (4.02 and 3.81 years versus 4.80 and 4.65 years). CONCLUSIONS Among kidney failure patients diagnosed with active surveillance-eligible prostate cancer during pretransplantation workup, the active surveillance and immediate listing strategy outperformed the alternative management strategies from a quality of life expectancy perspective, followed by definitive treatment and immediate listing.
Collapse
Affiliation(s)
- Uwe Bieri
- Department of Urology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland
| | - Kerstin Hübel
- Department of Nephrology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland
| | - Harald Seeger
- Department of Nephrology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland
| | - Girish S Kulkarni
- Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada
| | - Tullio Sulser
- Department of Urology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland
| | - Thomas Hermanns
- Department of Urology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland
| | - Marian S Wettstein
- Department of Urology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland .,Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
15
|
Kranzbühler B, Bieri U, Poyet C, Sulser T, Eberli D, Hermanns T. MP08-06 EFFICIENCY OF BLADDER WASH CYTOLOGY DURING SURVEILLANCE OF NON-MUSCLE INVASIVE BLADDER CANCER: ANALYSIS IN A CONTEMPORARY PATIENT COHORT. J Urol 2018. [DOI: 10.1016/j.juro.2018.02.311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
16
|
Kranzbühler B, Bieri U, Poyet C, Seifert B, Sulser T, Hermanns T. PD19-02 IS THERE A ROLE FOR UPPER URINARY TRACT IMAGING SURVEILLANCE IN THE FOLLOW-UP OF NON-MUSCLE INVASIVE BLADDER CANCER? J Urol 2017. [DOI: 10.1016/j.juro.2017.02.875] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
17
|
Bieri U, Moch H, Dehler S, Korol D, Rohrmann S. Changes in autopsy rates among cancer patients and their impact on cancer statistics from a public health point of view: a longitudinal study from 1980 to 2010 with data from Cancer Registry Zurich. Virchows Arch 2015; 466:637-43. [PMID: 25749838 DOI: 10.1007/s00428-015-1734-7] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2014] [Revised: 01/14/2015] [Accepted: 02/02/2015] [Indexed: 11/24/2022]
Abstract
During the last decades, autopsy rates have dramatically decreased in many countries. The Cancer Registry Zurich, which exists since 1980, provides the opportunity to address to what extent the number of autopsies in cancer patients has changed over a longer period of time and how often autopsies provide a diagnosis of clinically undetected cancer. Data from the Cancer Registry Zurich consisting of 102,434 cancer cases among 89,933 deceased patients between 1980 and 2010 were analyzed by means of descriptive statistics. The autopsy rate declined from 60 % in 1980 to 7 % in 2010. The total number of autopsies performed decreased from 1179 in 1986 to 220 in 2010. Furthermore, there was also a decline in the rate of newly detected tumours based on autopsy information. In 1980, the rate of newly detected tumours through autopsy was 42 % compared with 2010, when the rate had declined to 17 %. A consequence of the reduced autopsy rate is the reduction of incidental findings at autopsy in cancer registration. However, this reduction has not negatively affected the total incidence of cancer. It seems that the state-of-the-art diagnostic tools used for tumour detection are sufficiently reliable, allowing the scientific community to trust the quality of data provided by cancer registries in spite of decreasing autopsy rates.
Collapse
Affiliation(s)
- Uwe Bieri
- Division of Chronic Disease Epidemiology, Epidemiology, Biostatistics and Prevention Institute (EPBI), University of Zurich, Hirschengraben 84, 8001, Zürich, Switzerland
| | | | | | | | | |
Collapse
|